Kezar Life Sciences Inc.
KZR
NGS
Sector: Healthcare
Industry: Biotechnology
0.84
USD
0.00
(0.06%)
Optionable: Yes Market Cap: 63 M 90-day average vol: 566,136
Previous close: 0.8376 Open: 0.8544 Bid: 0.845 Ask: 0.8594
52 week range
0.67 7.61
Last updated: Monday 4th December 2023
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
🎉 Exciting news! 🎉
You are invited to join our Discord Channel.
Interact, learn, and grow with experts in the markets!
Join our DiscordMetrics
Valuation
Price per Sales TTM ($) | 9.27 |
Price per Book TTM ($) | 0.30 |
PE Ratio (TTM) | -1.00 |
Book Value per Share ($) | 2.97 |
5 Year PE Range | NA , NA |
Returns
7 Day Return | -6.20% | |
1 Month Return | -0.82% | |
3 Month Return | -44.53% | |
1 Year Return | -88.15% | |
3 Year Return | -87.11% | |
5 Year Return | -97.08% | |
YTD Return | -88.10% |
Risk
Analyst Estimates
Financial Health
Technicals
RSI (14 Day) | 45.74 |
14 Day SMA ($) | 0.85 |
14 Day EMA ($) | 0.85 |
Money Flow Index | 31.94 |
Average True Range | 0.07 |
50 Day SMA ($) | 0.91 |
200 Day SMA ($) | 2.31 |
ADX | 14.77 |
MACD | 0.15 |
Growth
Free Cash Flow QoQ Growth | 0.00% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | 0.00% |
Revenue QoQ Growth | 0.00% |
EPS YoY Growth | 0.00% |
Profitability
Financials
KZR Income Statement
Annual
| Invalid date | Dec-18 | Dec-19 | Dec-20 | Dec-21 | Dec-22 | |
|---|---|---|---|---|---|---|
| Basic EPS from continuing operations | -1.84 | -0.95 | -1.04 | |||
| Basic EPS total | -1.84 | -0.95 | -1.04 | -1.01 | ||
| Basic weighted shares outstanding | 10 M | 19 M | 44 M | 53 M | 67 M | |
| Depreciation | -700000.0 | 900000.0 | 900000.0 | 900000.0 | -1000000.0 | |
| DepreciationAndAmortization | -700000.0 | 900000.0 | 900000.0 | 900000.0 | -1000000.0 | |
| Diluted EPS total | -2.26 | -1.84 | -0.95 | -1.04 | -1.01 | |
| Diluted normalized net income/share | -2.26 | |||||
| Diluted weighted shares outstanding | 10 M | 19 M | 44 M | 53 M | 67 M | |
| GeneralAndAdministrativeExpense | 7 M | 10 M | 12 M | 16 M | 20 M | |
| Income before tax | -23 M | -35 M | -42 M | -55 M | -68 M | |
| Interest income | 2 M | 2 M | 1 M | 188000.0 | 4 M | |
| InterestExpenseNonOperating | 159000.0 | 1 M | ||||
| Net income from total operations | -23 M | -35 M | -42 M | -55 M | -68 M | |
| NetIncomeCommonStockholders | -23 M | -35 M | -42 M | -55 M | -68 M | |
| NetIncomeContinuousOperations | -23 M | -35 M | -42 M | -55 M | -68 M | |
| NetNonOperatingInterestIncomeExpense | 2 M | 2 M | 1 M | 29000.0 | 3 M | |
| Normalized income | -43 M | |||||
| Operating income | -25 M | -37 M | -43 M | -55 M | -71 M | |
| Operating income before depreciation (EBITDA) | -23 M | -35 M | -40 M | -51 M | -67 M | |
| OperatingExpense | 25 M | 37 M | 43 M | 55 M | -71 M | |
| OtherGandA | 7 M | 10 M | 12 M | 16 M | 20 M | |
| OtherOperatingExpenses | -25 M | 37 M | -487000.0 | -775000.0 | -71 M | |
| RentAndLandingFees | -1000000.0 | 1 M | 1 M | 1 M | 20 M | |
| Research & development expense | 18 M | 27 M | 31 M | 39 M | 51 M | |
| ResearchExpense | 18 M | 27 M | 31 M | 39 M | 51 M | |
| SalariesAndWages | -2 M | -14 M | ||||
| Selling Gen & administrative expense | 7 M | 10 M | 12 M | 16 M | 20 M | |
| Total Income available for interest expense (EBIT) | -23 M | -35 M | -42 M | -54 M | -67 M | |
| Total common shares outstanding | 19 M | 38 M | 48 M | 57 M | 71 M | |
| Total net income | -23 M | -35 M | -42 M | -55 M | -68 M | |
| Total ordinary shares | 73 M | 73 M | 73 M | 73 M | 73 M | |
| TotalExpenses | 25 M | 37 M | 43 M | 55 M | -71 M |
Call: 1-877-778-8358
Welcome! I'm Ankur, the founder/CEO of MarketXLS. With over six years of experience, I've helped 2500+ customers implement personalized investment research strategies and monitoring systems in Excel.
Implement “your own” investment strategies in Excel with thousands of MarketXLS functions and templates.
Get started today
Get started today